{
    "root": "456a5c4a-bc6b-40c1-9304-19749d58d894",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ethacrynic Sodium",
    "value": "20210714",
    "ingredients": [
        {
            "name": "ETHACRYNATE SODIUM",
            "code": "K41MYV7MPM"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        }
    ],
    "indications": {
        "text": "ethacrynic acid indicated treatment edema agent greater diuretic potential commonly employed required . 1.treatment edema associated congestive heart failure , cirrhosis liver , renal disease , including nephrotic syndrome . 2.short-term management ascites due malignancy , idiopathic edema , lymphedema . 3.short-term management hospitalized pediatric patients , infants , congenital heart disease nephrotic syndrome . 4.intravenous ethacrynate sodium injection indicated rapid onset diuresis desired , e.g . , acute pulmonary edema , gastrointestinal absorption impaired oral medication practicable .",
        "doid_entities": [
            {
                "text": "congestive heart failure (DOID:6000)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6000"
            },
            {
                "text": "cirrhosis (DOID:5082)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5082"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "nephrotic syndrome (DOID:1184)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1184"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "lymphedema (DOID:4977)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4977"
            },
            {
                "text": "congenital heart disease (DOID:1682)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1682"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "pulmonary edema (DOID:11396)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11396"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute pulmonary edema",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_330012"
            }
        ]
    },
    "contraindications": {
        "text": "must regulated carefully prevent rapid substantial loss fluid electrolyte indicated necessary . magnitude diuresis natriuresis largely dependent degree fluid accumulation present patient . similarly , extent potassium excretion determined large measure presence magnitude aldosteronism .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ethacrynate sodium injection , usp dry white material either plug form powder . supplied vials containing ethacrynate sodium equivalent 50 mg ethacrynic acid . ndc 67457-297-50carton containing one single-dose vial storage : store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] manufactured : mylan institutional llc morgantown , wv 26505 u.s.a. manufactured : gland pharma ltd hyderabad 500 043indiacode . : ap/drugs/103/97 pslea-019556-01 revised : 7/2021mi : ethaij : r2",
    "adverseReactions": "diuretics , including ethacrynic acid , contraindicated anuria . increasing electrolyte imbalance , azotemia , and/or oliguria occur treatment severe , progressive renal disease , diuretic discontinued . patients diuretic produced severe , watery diarrhea . occurs , discontinued used . experience infants accumulated , therapy oral parenteral ethacrynic acid contraindicated . hypersensitivity component product .",
    "indications_original": "Ethacrynic acid is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. \n                  \n                     \n                        1.Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.\n                     \n                        2.Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema.\n                     \n                        3.Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.\n                     \n                        4.Intravenous ethacrynate sodium for injection is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable.",
    "contraindications_original": "Dosage must be regulated carefully to prevent a more rapid or substantial loss of fluid or electrolyte than is indicated or necessary. The magnitude of diuresis and natriuresis is largely dependent on the degree of fluid accumulation present in the patient. Similarly, the extent of potassium excretion is determined in large measure by the presence and magnitude of aldosteronism.",
    "warningsAndPrecautions_original": "Ethacrynate Sodium for Injection, USP is a dry white material either in a plug form or as a powder. It is supplied in vials containing ethacrynate sodium equivalent to 50 mg of ethacrynic acid.\n                  NDC 67457-297-50carton containing one single-dose vial\n                  \n                     Storage: Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]\n                  \n                  Manufactured for:\n                     Mylan Institutional LLC\n                     Morgantown, WV 26505 U.S.A.\n                  Manufactured by:\n                     Gland Pharma Ltd\n                     Hyderabad 500 043IndiaCode No.: AP/DRUGS/103/97\n                  PSLEA-019556-01\n                  Revised: 7/2021MI:ETHAIJ:R2",
    "adverseReactions_original": "All diuretics, including ethacrynic acid, are contraindicated in anuria. If increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued.\n                  In a few patients this diuretic has produced severe, watery diarrhea. If this occurs, it should be discontinued and not used again.\n                  Until further experience in infants is accumulated, therapy with oral and parenteral ethacrynic acid is contraindicated.\n                  Hypersensitivity to any component of this product.",
    "drug": [
        {
            "name": "Ethacrynic Sodium"
        }
    ]
}